Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-reactive protein (CRP) in Obese Diabetic Women
NCT00262548Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Rosuvastatin with Placebo (2 arms). Primary endpoints: Glycosylated Hemoglobin at 6 months, Low-Density Lipoprotein Cholesterol at 6 months and 2 more. Started Oct 2005; status: completed.
02
Drugs
rosuvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00262548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262548.